Cambridge Healthtech Institute’s 3rd Annual

NASH and Fibrosis

Drug Discovery for Scarring of the Liver, Lung and other Organs

September 29-30, 2021

 

Fibrosis is the result of cells not recovering properly from injury which leads to scar tissue formation, often after prolonged inflammation. Fibrosis of the liver is also known as non-alcoholic steatohepatitis (NASH). Lung and liver are especially active areas of recent fibrosis drug discovery, with some of the leading phase 3 NASH drug candidates having been recently replaced by earlier-stage NASH candidates. For lung fibrosis, there are several drug candidates in clinical trials. Cambridge Healthtech Institute’s 3rd Annual NASH and Fibrosis conference covers clinical and earlier stage candidates for treating liver and lung fibrosis and possibly other organs such as kidney, skin and heart. A focus will be on targets or mechanisms shared by the fibrotic process across organs. Biologics, small molecules and newer drug modalities will be part of the agenda as will spotlights on early discovery and translation challenges such as developing better biomarkers and models for fibrosis. 

 

Who should attend: Immunologists, Discovery Biologists, Pharmacologists, Discovery Chemists, Scientists from Biotech, Pharma and Academics in departments such as: Immunology, Inflammation, Fibrosis, Metabolism, Liver Disease and Lung Disease

 

Coverage will include, but is not limited to:

 

  • Clinical stage NASH compounds and their targets (FXR, PPAR, THR-b, FGF21, Galectin)
  • Lung fibrosis drug candidates (especially for IPF)
  • Emerging fibrosis targets: TGFb, integrins, galectin, GPCRs, growth factors, extracellular matrix components and more 
  • Common targets between fibrosis and inflammation: ROCK, LOXL2 
  • Fibrosis biomarkers
  • New types of fibrosis cellular models (3D, stem cell)

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is March 29, 2021.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252

Email: ashah@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286

Email: reymael@healthtech.com


Submit a Speaker Proposal